- Home
- WHG vs LXRX Comparison
WHG vs LXRX Comparison
Compare WHG & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHG
- LXRX
- Stock Information
- Founded
- WHG 1983
- LXRX 1995
- Country
- WHG United States
- LXRX United States
- Employees
- WHG N/A
- LXRX N/A
- Industry
- WHG Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- WHG Finance
- LXRX Health Care
- Exchange
- WHG Nasdaq
- LXRX Nasdaq
- Market Cap
- WHG 147.1M
- LXRX 124.4M
- IPO Year
- WHG 2002
- LXRX 2000
- Fundamental
- Price
- WHG $15.95
- LXRX $0.50
- Analyst Decision
- WHG
- LXRX Buy
- Analyst Count
- WHG 0
- LXRX 4
- Target Price
- WHG N/A
- LXRX $3.67
- AVG Volume (30 Days)
- WHG 18.8K
- LXRX 31.4M
- Earning Date
- WHG 04-30-2025
- LXRX 03-06-2025
- Dividend Yield
- WHG 3.72%
- LXRX N/A
- EPS Growth
- WHG N/A
- LXRX N/A
- EPS
- WHG 0.26
- LXRX N/A
- Revenue
- WHG $94,721,000.00
- LXRX $31,081,000.00
- Revenue This Year
- WHG N/A
- LXRX N/A
- Revenue Next Year
- WHG N/A
- LXRX $101.91
- P/E Ratio
- WHG $61.46
- LXRX N/A
- Revenue Growth
- WHG 5.50
- LXRX 2481.48
- 52 Week Low
- WHG $11.01
- LXRX $0.28
- 52 Week High
- WHG $18.03
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- WHG 50.70
- LXRX 53.54
- Support Level
- WHG $15.73
- LXRX $0.32
- Resistance Level
- WHG $17.25
- LXRX $0.71
- Average True Range (ATR)
- WHG 0.61
- LXRX 0.06
- MACD
- WHG 0.03
- LXRX 0.03
- Stochastic Oscillator
- WHG 41.44
- LXRX 46.95
About WHG Westwood Holdings Group Inc
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals, and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high-net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.